Medical Management Of Placenta Accreta In A Primipara Following Vaginal Delivery
IOSR Journal of Dental and Medical Sciences · 2026-01 · 25 (1) · 10-03
DOI: 10.9790/0853-2501040103 ↗Kurz gefasst
Fachartikel in der Zeitschrift IOSR Journal of Dental and Medical Sciences, 2026-01. Verfasst von Dr Anubha Singh Chandel.
Abstract (Originalsprache)
The incidence of placenta accreta, a potentially life-threatening obstetric condition has increased over the years. Women at greatest risk of placenta accreta are those who have myometrial damage caused by a previous cesarean delivery. Morbidly adherent placenta in the absence of risk factors is a rare entity in primigravida, and its conservative management becomes important in such patients to preserve future fertility. Here we present a case of placenta accreta in a primigravida with no known risk factors. The diagnosis was made following delivery where attempted, failed manual removal of placenta raised suspicion due lack of plane of separation between placenta and uterus. Diagnosis was confirmed by MRI and medical management with methotrexate was successfully done. Weekly follow-ups with clinical evaluation, serum beta Human Chorionic Gonadotropin, CBC, LFT and creatinine levels were done. Also two weekly imagings were done to look for placental morphological changes and vascularity
Zitieren
APA
Chandel, D. A. S. (2026). Medical Management Of Placenta Accreta In A Primipara Following Vaginal Delivery. IOSR Journal of Dental and Medical Sciences, 25(1), 10-03. https://doi.org/10.9790/0853-2501040103
Vancouver
Chandel DAS. Medical Management Of Placenta Accreta In A Primipara Following Vaginal Delivery. IOSR Journal of Dental and Medical Sciences. 2026;25(1):10-03. doi:10.9790/0853-2501040103
BibTeX
@article{Chandel2026,
author = {Chandel, Dr Anubha Singh},
title = {Medical Management Of Placenta Accreta In A Primipara Following Vaginal Delivery},
journal = {IOSR Journal of Dental and Medical Sciences},
year = {2026},
volume = {25},
number = {1},
pages = {10--03},
doi = {10.9790/0853-2501040103}
}
EUVIMED